Format

Send to

Choose Destination
J Cancer. 2011;2:324-8. Epub 2011 May 28.

Targeting EGFR in Triple Negative Breast Cancer.

Author information

1
1. Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Abstract

Our preliminary data show that erlotinib inhibits Triple-negative breast cancer (TNBC) in a xenograft model. However, inhibition of metastasis by erlotinib is accompanied by nonspecific effects because erlotinib can inhibit other kinases; thus, more direct targets that regulate TNBC metastasis need to be identified to improve its therapeutic efficacy.

KEYWORDS:

EGFR; erlotinib; metastasis; triple negative breast cancer; tyrosine kinase inhibitor

PMID:
21716849
PMCID:
PMC3119395

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center